



ECNP Roadmap Meeting on Precision Psychiatry 2027

Prospectus for supporters

The ECNP Roadmap Meeting on Precision Psychiatry 2027

Making precision psychiatry a reality

The ECNP Roadmap Meeting brings together 150 international opinion leaders from the research, clinical, pharma, regulatory, and patient communities for one and a half days of focused exchange and discussion. Hosted by Europe's leading independent scientific association for the science and treatment of disorders of the brain, the meeting has become an indispensable platform for driving precision medicine in neuropsychiatry.

Supporting the meeting offers companies and organisations with an investment in mental health and neuropsychiatric treatment development priority recognition in ECNP's global stakeholder campaign to set psychiatric treatment research on a more scientifically robust basis and to open the way to more viable drug discovery and development and better patient outcomes.

From signals to stratification: building evidence for precision psychiatry

25-26 January 2027, Amsterdam, The Netherlands, and Virtually

Part of ECNP's Roadmap initiative to incorporate new scientific evidence on an ongoing basis into a biologically informed framework for mental disorders, this high-impact event will spotlight the urgent need to move from conceptual frameworks to real-world implementation.

Building on previous successful meetings exploring scientific foundations, methodological approaches, and biomarker-driven strategies, this year's meeting will focus on how the field can transition toward precision psychiatry in clinical trials. Key topics will include when and how mechanisms matter, how emerging technologies can improve the definition of patient populations, and whether artificial intelligence can support target identification and enrichment strategies.

The meeting will also examine how clinical trial design must evolve to enable a biologically informed psychiatry that is clinically meaningful, interpretable, and ready for regulatory

pathways. A central aim will be to integrate lessons learned from failed or non-replicated studies and explore how biological evidence can be incorporated into psychiatry, while preserving the complexity and clinical relevance of mental disorders.

Precision psychiatry offers a transformative approach to understanding and treating mental illness—rooted in objective, biologically informed markers rather than symptom-based categories. This meeting will bring together all the key stakeholders, including:

- Regulatory authorities
- Clinicians and researchers
- Industry leaders
- Health technology assessors
- Payers and policymakers
- Patient advocacy groups

Together, we will explore how to translate advances in biology, technology, and data science into clinically meaningful and implementable approaches for precision psychiatry.

Key themes include:

- Defining when biological mechanisms can improve clinical trial success
- Developing strategies for patient stratification and enrichment
- Leveraging AI and emerging technologies to identify targets and improve trial design
- Learning from failed and non-replicated studies
- Integrating biological evidence while maintaining clinical relevance
- Building a regulatory-ready pathway for precision psychiatry

Please join us in Amsterdam and help transform mental health care through science, innovation, and collaboration.

When:	25-26 January 2027
Where:	Van der Valk Hotel Amsterdam Zuidas Tommaso Albinonistraat 200, 1083 HM Amsterdam
Audience:	150 opinion leaders from the research, clinical, pharma, regulatory, HTA, payer, patient advocacy and policy-making communities
Participation:	By application and selection
Website:	https://www.ecnp.eu/meetings/roadmap-meeting-on-precision-psychiatry/

Provisional programme

MONDAY 25 JANUARY 2027

- 13.30-14.00 Registration and welcome coffee
- 14.00-14.15 **Welcome and introduction**
Martien Kas, NL – Chair of the Programme Committee
- 14.15-15.00 Opening keynote lecture
Hugh Marston, DE
- 15.00-15.15 Discussion and Q&A
- 15.15-18.00 **Session 1: From early signals to confirmatory evidence: learning from failures in precision psychiatry trials**
- 15.15-15.45 Aticaprant and the enrichment problem: what went wrong and what should be tested next?
- 15.45-16.15 Coffee break
- 16.15-16.45 When mechanisms fail to translate: lessons for precision psychiatry development
- 16.45-17.15 Precision psychiatry in postpartum depression: insights from recent clinical trials
- 17.15-18.00 Panel discussion: From failure to repositioning: what would we do differently?
All faculty session 1
- 18.00 - 19.15 **Networking drinks**

WEDNESDAY 26 JANUARY 2027

- 08.15-10.10 **Session 2: Precision neuroscience methodology: enrichment, biomarkers, AI and confirmatory design**
Chair: Derek Buhl, US
- 08.15-08.35 Precision neuroscience trial methodology: enrichment, biomarkers, surrogates and AI in drug development
- 08.35-08.55 Precision psychiatry in major depression: genetically guided treatment response to Nelivaptan in the phase 2 OLIVE trial

- 08.55-09.15 Explainable AI for trial enrichment: from retrospective discovery to prospective testing[
- 09.15-09.35 Proof-of-concept precision prevention: hormone sensitivity and perinatal depression
- 09.35-10.10 Panel discussion: From discovery tools to confirmatory trial design
All faculty session 2

10.10-10.40 **Coffee break**

10.40-12.30 **Session 3: Building the Precision Psychiatry ecosystem: platforms, collaboration and regulatory readiness**

Chair: Andreas Reif, DE

- 10.40-11.00 From precompetitive collaboration to regulatory acceptance
- 11.00-11.20 Platform trials and adaptive methodology in psychiatry research
- 11.20-11.40 ADNI, data platforms and the future of Precision Psychiatry infrastructure
- 11.40-11.55 ECNP initiatives: EU-MIC , and the Biomarker Mapping Project
- 11.55-12.30 Panel discussion - What must happen in the next five years for Precision Psychiatry to succeed?
All faculty session 3
- 12.30-12.35 Closing of the Precision Psychiatry Roadmap Meeting 2027
Martien Kas, NL

About ECNP

ECNP is Europe's leading independent forum for the science of CNS treatments. The ECNP Congress showcases the world's best disease-oriented brain research, annually attracting some 7,600 psychiatrists, neuroscientists, neurologists and psychologists from around the world. The College's wide range of scientific and educational activities, programmes and events make it one of the largest non-institutional supporters of applied and translational neuroscience research and education in Europe. A founder member of the European Brain Council, ECNP also has extensive outreach experience through its press activities, epidemiological and policy studies, and engagement with stakeholders across the treatment lifecycle and throughout the wider brain health community.

How to support the meeting

ECNP invites organisations and companies interested in advancing the science of precision psychiatry to become a supporter of the meeting.

Contributing Partner (€30,000)

For a €30,000 contribution, Contributing Partners will receive:

- Acknowledgement statement and prominent logo placement in the meeting informational material:
 - Meeting website
 - Introductory and closing slides
 - Supporter banner displayed at the meeting venue
- Two complimentary in-person registrations

SME supporter (€5,000)

An SME has less than 250 staff members and a turnover less than € 50 million (or balance sheet of less than € 43 million).¹

For a €5,000 contribution, SME Supporters will receive:

- Acknowledgement statement and logo placement in the meeting informational material, with logos displayed in a smaller format than those of Contributing Partners:
 - Meeting website
 - Introductory and closing slides
 - Supporter banner displayed at the meeting venue
- No complimentary registrations included

For further details please contact ECNP at **roadmap@ecnp.eu**.

Companies and organisations supporting the meeting should be aware that the ECNP Roadmap Meeting is a multi-supporter event. The nature of the stakeholder interaction that is at the heart of the meeting precludes sole-sponsor arrangements.

¹ https://single-market-economy.ec.europa.eu/smes/sme-fundamentals/sme-definition_en.

The ECNP Roadmap Initiative

The right treatment for the right patient at the right time.

Current nosology for the diagnosis of neuropsychiatric disorders separates each disorder often into non-overlapping diagnostic categories. This nosological separation is not based on underlying aetiology but on convention-based clustering of qualitative symptoms of disorders. Yet, overlap in disease symptoms and dimensions across different neuropsychiatric disorders is huge, leading to considerable comorbidity between disorders.



While diagnostic categories are sufficient to provide the basis for general clinical management, they do not describe the underlying neurobiology that gives rise to individual symptoms. The ability to precisely link these symptoms to underlying neurobiology would not only facilitate the development of new and more precise treatments – which are urgently needed given the unsatisfyingly low response and remission rates of current treatments of all modalities – it would also allow physicians to provide patients with a better understanding of the complexities and management of their illness. To realise this ambition, a paradigm shift is needed to build an understanding of how neuropsychiatric conditions can be defined more precisely using quantitative, multimodal biological and environmental processes and parameters and thus to optimise treatment efficacy.

Precision psychiatry has been introduced as a new approach to improve treatment of mental disorders and to develop innovative, mechanism-based treatment strategies beyond the current diagnostic boundaries. At its core, precision psychiatry is an approach that focuses on understanding the underlying neurobiological mechanisms that cause the symptoms of mental health conditions. Using this understanding, it aims to develop therapies that can target these mechanisms, which in turn will address previously untreatable aspects of mental health conditions by providing more specific symptom control and possibly altering the trajectory of the disease process. However, this new approach would result in a radically different diagnostic system, abandoning the classical clinical approach, and posing significant challenges for clinicians, industry, and regulators alike.

The ECNP Roadmap Initiative aims to reach a consensus roadmap for building a new diagnostic framework for mental disorders that will instantiate a set of principles and procedures by which research can continuously improve precision diagnostics. The initiative seeks to achieve global alignment with all stakeholders on the way forward to better define and (longitudinally) measure neuropsychiatric conditions, harmonise (translational) methodologies and data sets across the community, and mobilise resources to implement and validate the framework.



Read the Roadmap perspective paper [here](#).